Ed Biotech announced on September 15 that the company's self-developed AmoyDxHRD Complete Panel has been certified by the “In Vitro Diagnostic Medical Device Regulations” issued by TUV Süddeutsche Group, an EU notifier. It can be used as an accompanying diagnostic product to assist in identifying patients with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 gene mutations to help screen patients who have previously been treated with novel hormonal drugs and are progressing.

Ed Biotech announced on September 15 that the company's self-developed AmoyDxHRD Complete Panel has been certified by the “In Vitro Diagnostic Medical Device Regulations” issued by TUV Süddeutsche Group, an EU notifier. It can be used as an accompanying diagnostic product to assist in identifying patients with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 gene mutations to help screen patients who have previously been treated with novel hormonal drugs and are progressing.